The FDA is cracking down on a loophold drug companies use to avoid the requirement that they study products in children; a new study finds nearly 6 in 10 Hispanic adults cite a language or cultural barrier that makes it difficult for them to communicate with healthcare providers; a judge has ordered Wisconsin to pay for gender reassignment surgery for 2 Medicaid recipients.
Since the Pediatric Research Equity Act was passed in 2003, drug companies have been skirting the requirement that they study some products in children by designating more drugs as orphan drugs. Bloomberg reported that the FDA will close that loophole by cracking down on what it considers an orphan drug. According to the exemption, an orphan drug didn’t need to be researched in pediatric populations since the drugs treat diseases affecting a small number of people.
A new study from The Associated Press-NORC Center for Public Affairs Research found nearly 6 in 10 Hispanic adults cite a language or cultural barrier that makes it difficult for them to communicate with healthcare providers. Hispanics also noted concerns that these barriers create for people seeking long-term care services. Of those who do face barriers, about half turn to a family member or another healthcare provider, while 1 in 4 look to a translator, public resources, or online sources.
Two transgender Medicaid recipients in Wisconsin will have their surgeries paid for by the state after a federal judge weighed in. The beneficiaries filed the lawsuit over a 1996 state rule that denies coverage for “transsexual” surgeries, The Hill reported. They argued that the state denying their coverage violated the Affordable Care Act and their rights to equal protection. The judge said that the “likelihood of ongoing, irreparable harm” that the 2 beneficiaries could face outweighed “concerns regarding public health or limiting costs.”
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More